Abstract
ACTwatch is a multi-country research project designed to fill evidence gaps on malaria diagnostics, antimalarial medicines and fever case management in the private and public health sectors. Standardized tools and approaches are employed to provide comparable data across countries and over time.
ACTwatch was launched in 2008 with funding from the Bill and Melinda Gates Foundation (BMGF), and is currently implemented in 10 countries (see Figure 1) with funding from the BMGF, UNITAID, and the DFID.
ACTwatch is designed to provide timely, relevant, and high quality antimalarial market evidence. The goal of providing this market evidence is to inform and monitor national and global policy, strategy, and funding decisions for improving malaria case management. ACTwatch monitors antimalarial markets in the context of policy shifts and investments in the scale-up of first-line ACT and blood testing using RDTs. This has included adaptation of project methods for the evaluation of the Affordable Medicines Facility-malaria (AMFm) pilot.
